Effects of a New Formulation of Multiple-Action Tear Substitute on Objective Ocular Surface Parameters and Ocular Discomfort Symptoms in Patients with Dry Eye Disease

Introduction

Dry eye disease (DED) represents one of the most common ocular disorders encountered in clinical practice, with a reported prevalence of 5% to 50% in the adult population.

Tear supplementation is the mainstay of the current management of DED. Recently, there has been a progressive shift from simple drugs that add water to complex multi-action combination formulas aimed at disrupting different mechanisms within the vicious cycle of dry eye disease (DED). This study evaluated the efficacy and tolerability of Trimix eye drops (Off Health Italia, Italy), a combination of viscosity-enhancing hyaluronic acid, trehalose, and cationic liposomes comprising stearylamine and phospholipids, in patients with DED.

In this study, 25 patients diagnosed with mild to moderate DED were enrolled and treated with Trimix eye drops three times daily for 2 months.

Improvement of evaluation parameters

Trimix eye drops is a combination of viscosity-enhancing hyaluronic acid, trehalose, and cationic liposomes comprising stearylamine and phospholipids, which has shown promising results in both animal and ex vivo models of DED.

Trimix eye drops administered three times daily for 2 months resulted in significant improvement in non-invasive break-up time (NIBUT), tear meniscus height (TMH) and lipid layer thickness (LLT) in patients with mild to moderate DED. Trimix eye drops also significantly improved symptoms of ocular discomfort by showing a good tolerability profile.